Autolus Therapeutics plc
AUTL
$2.03
-$0.08-3.79%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 117.39M | 92.62M | 75.39M | 51.13M | 29.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 117.39M | 92.62M | 75.39M | 51.13M | 29.93M |
| Cost of Revenue | 204.97M | 208.48M | 207.38M | 186.51M | 170.30M |
| Gross Profit | -87.58M | -115.85M | -132.00M | -135.38M | -140.36M |
| SG&A Expenses | 159.52M | 148.62M | 138.20M | 138.78M | 129.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 364.48M | 357.10M | 345.59M | 325.29M | 300.13M |
| Operating Income | -247.09M | -264.47M | -270.20M | -274.17M | -270.20M |
| Income Before Tax | -279.48M | -288.36M | -285.56M | -220.19M | -223.67M |
| Income Tax Expenses | 677.00K | 609.00K | 1.97M | 4.62M | 4.11M |
| Earnings from Continuing Operations | -280.16 | -288.97 | -287.53 | -224.80 | -227.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -280.16M | -288.97M | -287.53M | -224.80M | -227.78M |
| EBIT | -247.09M | -264.47M | -270.20M | -274.17M | -270.20M |
| EBITDA | -236.57M | -254.24M | -260.38M | -264.91M | -261.54M |
| EPS Basic | -1.05 | -1.09 | -1.08 | -0.84 | -0.86 |
| Normalized Basic EPS | -0.66 | -0.68 | -0.67 | -0.52 | -0.53 |
| EPS Diluted | -1.05 | -1.09 | -1.08 | -0.84 | -0.86 |
| Normalized Diluted EPS | -0.66 | -0.68 | -0.67 | -0.52 | -0.53 |
| Average Basic Shares Outstanding | 1.06B | 1.06B | 1.06B | 1.06B | 1.06B |
| Average Diluted Shares Outstanding | 1.06B | 1.06B | 1.06B | 1.06B | 1.06B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |